Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safetyLugano, Switzerland, February 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to note two recent journal publications on the u.
Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety Lugano, Switzerland, February 18, 2021 - Helsinn, a Swiss pharmaceutical group focused
SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study)
(UroToday.com) During the second prostate cancer session at the 2020 Annual Meeting of the Society of Urologic Oncology (SUO), Drs. Neal Shore and Ashley Evan Ross debated the use of relugolix as a new standard of care for androgen deprivation therapy (ADT) for the treatment of prostate cancer.
This debate follows the publication of the HERO trial,
1
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO), which was published in the New England Journal of Medicine in June 2020 and of which Dr. Shore is the lead author. This was a randomized controlled comparing relugolix, an oral gonadotropin-releasing hormone antagonist, to leuprolide. 120mg relugolix was given by mouth daily and leuprolide was given every 3 months as depot injections. The primary end point was “sustained castration”, meaning a testosterone level